SNDX
HealthcareSyndax Pharmaceuticals, Inc.
$20.22
$-1.08 (-5.07%)
Jan 5, 2026
Price History (1Y)
Analysis
Syndax Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector, with a market capitalization of $1.76 billion and approximately 270 employees. The company's revenue for the trailing twelve months (TTM) was $111.30 million. The financial health of Syndax Pharmaceuticals, Inc. indicates significant losses, as evidenced by negative margins across various metrics: gross margin (-119.7%), operating margin (-125.2%), and profit margin (-279.9%). The company's returns on equity (-129.3%) and assets (-39.2%) are also negative. However, the debt-to-equity ratio is substantial at 299.26, while the current ratio is relatively strong at 4.64. Additionally, the cash balance stands at $454.17 million, with a debt of $345.43 million. The valuation context for Syndax Pharmaceuticals, Inc. shows a forward P/E ratio of -11.62 and an EV/EBITDA of -5.68. The company's revenue growth over the past year was 267.0%. There is no dividend yield or payout ratio available.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Visit website →Key Statistics
- Market Cap
- $1.76B
- P/E Ratio
- N/A
- 52-Week High
- $22.73
- 52-Week Low
- $8.58
- Avg Volume
- 2.61M
- Beta
- 0.48
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 270